A Comprehensive Monograph on Levosimendan: Pharmacology, Clinical Evidence, and Therapeutic Placement

Section 1: Drug Profile and Introduction

1.1. Overview and Classification

Levosimendan is a small molecule drug that represents a distinct class of cardiotonic agents known as calcium sensitizers.[1] Due to its combined positive inotropic (contractility-enhancing) and vasodilatory properties, it is also functionally classified as an "inodilator".[3] It was developed to address the significant limitations of traditional inotropic agents, such as catecholamines (e.g., dobutamine) and phosphodiesterase-III (PDE-III) inhibitors (e.g., milrinone). These conventional agents exert their effects primarily by increasing intracellular calcium concentrations, a mechanism that, while increasing cardiac output, also elevates myocardial oxygen demand and carries a significant risk of tachyarrhythmias and increased mortality.[2] Levosimendan's novel mechanism of action is designed to enhance cardiac performance more efficiently, aiming to circumvent these critical liabilities.[7]

The primary approved indication for Levosimendan, marketed most commonly under the trade name Simdax, is the short-term treatment of acutely decompensated severe chronic heart failure (ADHF) in hospitalized patients for whom conventional therapy is insufficient and inotropic support is deemed necessary.[1] It is currently approved for this use in approximately 60 countries worldwide but remains investigational in the United States and Canada.[1]

1.2. Chemical Identity and Physicochemical Properties

Levosimendan is the pharmacologically active (R)-enantiomer of the racemic compound simendan.[10] From a chemical standpoint, it is a pyridazinone-dinitrile derivative, possessing functional groups that classify it more broadly as a hydrazone, a pyridazinone, and a nitrile.[2] In its pure form, Levosimendan is a yellow crystalline powder.[12] For clinical use, it is formulated as a clear yellow to orange concentrated solution (2.5 mg/mL) intended for intravenous infusion after dilution.[1] This formulation is necessary because Levosimendan is only minimally soluble in water at physiological pH and is moderately lipophilic.[11] The commercial preparation contains povidone, citric acid, and a significant quantity of anhydrous ethanol as a solubilizing agent, a factor that must be considered in clinical practice.[11]

A consolidated summary of its key identifiers and chemical properties is provided in Table 1.

Table 1: Levosimendan Drug Identification and Chemical Properties

Property	Value	Source(s)
Generic Name	Levosimendan	7
Common Trade Names	Simdax, Daxim, Zimino	1
DrugBank ID	DB00922	1
CAS Number	141505-33-1	1
Type / Modality	Small Molecule	7
Chemical Formula	C14​H12​N6​O	1
Molecular Weight (Average)	280.291 g·mol⁻¹	1
IUPAC Name	2-phenyl]hydrazinylidene]propanedinitrile	1
SMILES	C[C@@H]1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N	2
InChIKey	WHXMKTBCFHIYNQ-SECBINFHSA-N	1
ATC Code	C01CX08 (Other cardiac stimulants)	1
Synonyms	(R)-Simendan, (-)-OR-1259, OR 1259	10

Section 2: Molecular Pharmacology: A Tripartite Mechanism of Action

Levosimendan's unique pharmacological profile stems from a combination of three distinct but synergistic mechanisms: calcium sensitization, vasodilation via potassium channel activation, and cardioprotection. This multifaceted action sets it apart from other inotropic agents.

2.1. Primary Mechanism: Calcium Sensitization (Inotropy)

The principal inotropic effect of Levosimendan is achieved through its binding to the N-terminal domain of cardiac troponin C (cTnC).[1] This interaction is the defining characteristic of its drug class. A critical feature of this binding is that it is

calcium-dependent; Levosimendan preferentially binds to troponin C only when it is already saturated with calcium, a state that occurs during cardiac systole.[1] By binding, it stabilizes the calcium-induced conformational change in the troponin complex. This stabilization enhances and prolongs the interaction between the contractile proteins actin and myosin, resulting in an increased force of contraction.[1]

This mechanism is fundamentally different from that of traditional inotropes. Agents like dobutamine and milrinone increase intracellular cyclic AMP (cAMP), which in turn elevates intracellular calcium levels to drive contractility.[5] This process is metabolically expensive, requiring significant ATP and thus increasing myocardial oxygen consumption (MVO2), which can be deleterious in an already compromised heart.[5] Levosimendan bypasses this pathway for its primary inotropic effect. It does not increase the concentration of intracellular calcium but rather "makes better use" of the calcium that is cyclically available within the myocyte.[1] This results in a more "energy-efficient" inotropy, a significant theoretical advantage in the fragile metabolic environment of ADHF or postcardiotomy shock, where myocardial oxygen supply is often limited.[3]

Furthermore, because the binding affinity of Levosimendan for troponin C diminishes as intracellular calcium levels fall during diastole, the drug's effect wanes, allowing for normal or even improved ventricular relaxation (a positive lusitropic effect).[7] This is a key distinction from agents that cause calcium overload, which can stiffen the ventricle and impair diastolic filling.[23]

2.2. Secondary Mechanism: Vasodilation (Inodilation)

In addition to its inotropic action, Levosimendan induces potent vasodilation by activating adenosine triphosphate (ATP)-sensitive potassium (KATP​) channels in the cell membranes of vascular smooth muscle cells.[1] The opening of these channels leads to potassium efflux, hyperpolarization of the cell membrane, and subsequent relaxation of the smooth muscle. This effect occurs in systemic and coronary arteries as well as systemic veins, producing a balanced reduction in both cardiac preload (the stretch on the heart at the end of diastole) and afterload (the resistance the heart must pump against).[1] This unloading of the heart reduces its overall workload, complementing the inotropic effect.

The combination of these two primary actions—inotropy and vasodilation—is what defines Levosimendan as an inodilator. These effects are not merely additive but synergistic. The afterload reduction makes it easier for the more forcefully contracting heart to eject blood, leading to a greater improvement in cardiac output and stroke volume than either mechanism would produce alone. This dual action explains its efficacy in low-output heart failure states and is central to its pharmacological profile.[1]

2.3. Tertiary Mechanisms: Cardioprotection and PDE-III Inhibition

Levosimendan possesses additional mechanisms that contribute to its overall clinical effect, particularly in the context of myocardial ischemia.

Cardioprotection: The drug has been shown to open KATP​ channels located in the inner mitochondrial membrane of cardiomyocytes.[5] This action is mechanistically linked to the phenomenon of ischemic preconditioning, a process whereby brief periods of ischemia protect the heart from subsequent, more prolonged ischemic insults. This mitochondrial action is thought to confer anti-stunning and anti-ischemic effects, potentially mitigating myocardial injury, which may be particularly beneficial for patients with ischemic cardiomyopathy or those undergoing cardiac surgery.[5]

Phosphodiesterase-III (PDE-III) Inhibition: Levosimendan also exhibits a selective inhibitory action on the PDE-III enzyme, the same target as the inodilator milrinone.[2] While some reports indicate potent inhibition with low nanomolar

IC50​ values [10], this effect is generally considered to be a minor contributor to Levosimendan's overall clinical profile at standard therapeutic concentrations. It is possible that this mechanism becomes more clinically relevant at the higher end of the dosing range.[7]

Section 3: Clinical Pharmacology: Pharmacokinetics and Pharmacodynamics

The clinical application of Levosimendan is profoundly influenced by its unique pharmacokinetic and pharmacodynamic properties, most notably the extended duration of action conferred by a long-lived active metabolite.

3.1. Pharmacokinetics (PK): The Tale of the Active Metabolite

Absorption and Distribution: While an oral formulation is currently under investigation in Phase 3 trials, the approved formulation is for intravenous administration only. If administered orally, Levosimendan demonstrates high bioavailability of approximately 85%.[1] Following intravenous administration, the drug is highly bound to plasma proteins (97–98%), primarily albumin, and has a relatively small volume of distribution of approximately 0.3 L/kg.[1]

Metabolism and Elimination: Levosimendan undergoes extensive hepatic metabolism. The vast majority of the drug is conjugated with glutathione to form inactive metabolites that are subsequently excreted. However, a minor but clinically critical metabolic pathway exists. Approximately 5% of the dose undergoes reduction in the intestine to an amine metabolite, OR-1855. This intermediate is then N-acetylated in the liver to form the pharmacologically active metabolite, OR-1896.[2]

The pharmacokinetic profiles of the parent drug and its active metabolite are starkly different. Levosimendan itself has a very short elimination half-life of approximately 1 hour.[1] In contrast, the active metabolite, OR-1896, has an extremely long elimination half-life of

75–80 hours.[1] This metabolite, which shares the inodilatory properties of the parent compound, is responsible for the sustained hemodynamic effects observed long after the initial infusion has been completed. Final elimination of the parent drug and its metabolites occurs via both urine (54%) and feces (44%).[1]

This "pharmacokinetic disconnect" between the short half-life of the parent drug and the long duration of its clinical effect is the single most important concept in understanding its clinical use. For clinicians accustomed to agents like dobutamine, where effects dissipate rapidly upon cessation of the infusion, Levosimendan presents a different paradigm. Stopping the Levosimendan infusion does not terminate the drug's action; the OR-1896 metabolite continues to exert its inodilatory effects for many days.[3] This has profound implications for safety and monitoring. It underlies the stringent contraindications for the drug, such as severe hypotension or significant ventricular outflow obstruction, where a prolonged and not easily reversible hemodynamic effect could be catastrophic.[1] It also dictates the need for extended patient monitoring for at least 3–5 days post-infusion, as adverse effects like hypotension can manifest or persist long after the drug has been discontinued.[27] This pharmacokinetic profile makes careful patient selection paramount; the ideal candidate must be able to tolerate a sustained period of inodilation.

Dosing and the Loading Dose Controversy: The Summary of Product Characteristics (SmPC) and early clinical trials describe the use of an initial loading dose (e.g., 6–12 mcg/kg over 10 minutes) to rapidly achieve therapeutic plasma concentrations of the parent drug.[21] However, this practice has become controversial and is often avoided in modern clinical protocols. The primary dose-limiting side effect of Levosimendan is hypotension, driven by its potent vasodilatory action.[1] Administering a rapid bolus can precipitate a sudden and profound drop in blood pressure, which is particularly dangerous in hemodynamically fragile patients. Consequently, many clinicians and hospital protocols now favor omitting the loading dose and initiating therapy with the maintenance infusion (e.g., 0.1 mcg/kg/min) to allow for a more gradual and controlled hemodynamic response.[25] This reflects a clinical evolution where the risk of bolus-induced hypotension is deemed to outweigh the benefit of a slightly faster onset of action.

3.2. Pharmacodynamics (PD): Sustained Hemodynamic Effects

The pharmacodynamic effects of Levosimendan are a direct reflection of its mechanisms of action and unique pharmacokinetics. A single 24-hour infusion produces hemodynamic improvements that persist for at least 7–10 days, driven by the long-acting OR-1896 metabolite.[3]

Clinical trials have consistently demonstrated dose-dependent hemodynamic changes, including:

• An increase in cardiac output (CO) and stroke volume (SV).
• A decrease in pulmonary capillary wedge pressure (PCWP), a surrogate for left ventricular filling pressure (preload).
• A decrease in systemic vascular resistance (SVR), a measure of afterload.
• A decrease in mean arterial pressure (MAP) and pulmonary artery pressure (PAP).[3]

In addition to these direct hemodynamic effects, Levosimendan administration leads to a rapid and sustained reduction in plasma concentrations of B-type natriuretic peptide (BNP), a key biomarker of ventricular wall stress and a prognostic marker in heart failure.[1]

Section 4: The Pivotal Trials: A Critical Appraisal of the Evidence

The clinical evidence base for Levosimendan is complex and has been shaped by three pivotal, large-scale randomized controlled trials: LIDO, REVIVE II, and SURVIVE. The evolution of their findings tells a compelling story about the challenges of drug development in acute heart failure and has led to the current clinical uncertainty surrounding the drug's role.

4.1. The LIDO Study (Levosimendan Infusion versus Dobutamine)

The LIDO study, published in The Lancet in 2002, was the first major trial to generate significant enthusiasm for Levosimendan.[21] It was a multicenter, randomized, double-blind, double-dummy trial that enrolled 203 patients with severe low-output heart failure who were judged to require intravenous inotropic support.[21] Patients were randomized to receive a 24-hour infusion of either Levosimendan or dobutamine.[21] The primary endpoint was a composite measure of hemodynamic improvement at 24 hours, defined as an increase in cardiac output of 30% or more and a concurrent decrease in PCWP of 25% or more.[21]

The results were strongly in favor of Levosimendan. The primary endpoint was achieved in 28% of patients in the Levosimendan group compared to only 15% in the dobutamine group (hazard ratio 1.9, p=0.022).[21] More strikingly, the study reported a significant survival benefit. All-cause mortality at 180 days was substantially lower in the Levosimendan group (26%) compared to the dobutamine group (38%), with a hazard ratio of 0.57 (p=0.029).[21] The trial also noted that Levosimendan's beneficial effects were not attenuated by concomitant beta-blocker therapy, a key advantage over dobutamine.[28]

4.2. The REVIVE II Study (Randomized Multicenter Evaluation of Intravenous Levosimendan Efficacy)

The REVIVE II study sought to evaluate Levosimendan against placebo in patients with ADHF. It was a randomized, double-blind trial that enrolled 600 patients hospitalized for ADHF with dyspnea at rest despite standard diuretic therapy.[34] The primary endpoint was a novel composite of clinical status, assessing whether patients improved, worsened, or remained unchanged over a 5-day period.[34]

The trial successfully met its primary endpoint. Compared to placebo, significantly more patients treated with Levosimendan experienced clinical improvement, and significantly fewer experienced clinical worsening (p=0.015).[34] Levosimendan-treated patients also had greater reductions in BNP levels and a shorter mean duration of initial hospitalization (7.0 vs 8.9 days, p=0.006).[35]

However, these benefits came at a cost. The Levosimendan group experienced a higher incidence of adverse events, most notably hypotension and atrial fibrillation.[30] Most concerning was a numerically higher, though not statistically significant, 90-day mortality rate in the Levosimendan arm (15.1%) compared to the placebo arm (11.6%).[35] The publication of these results was controversially delayed by nearly eight years, a fact that has been subject to significant editorial commentary regarding the need for timely reporting of neutral or negative trial data.[38]

4.3. The SURVIVE Study (Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support)

The SURVIVE study was designed to be the definitive mortality trial, building on the promising survival signal from LIDO. Published in JAMA in 2007, it was the largest Levosimendan trial, enrolling 1327 patients with ADHF requiring inotropic support in a randomized, double-blind, double-dummy comparison against dobutamine.[31] The primary endpoint was all-cause mortality at 180 days, with the study powered to detect an ambitious 25% reduction in mortality with Levosimendan.[31]

The trial failed to meet its primary endpoint. All-cause mortality at 180 days was not significantly different between the groups: 26% in the Levosimendan group versus 28% in the dobutamine group (HR 0.91; 95% CI, 0.74-1.13; p=0.40).[1] Although Levosimendan produced a significantly greater reduction in BNP levels that persisted for 5 days, this did not translate into an improvement in any of the secondary clinical outcomes, including 31-day mortality or days alive and out of the hospital.[31] In terms of safety, Levosimendan was associated with a higher incidence of atrial fibrillation and hypokalemia, while cardiac failure was reported more frequently as an adverse event in the dobutamine group.[32]

The chronological progression of these trials illustrates a classic "promise versus reality" narrative in clinical drug development. The dramatic mortality benefit seen in the smaller LIDO study created high expectations that were not met in the larger, more definitive SURVIVE trial. This pattern is a common phenomenon in clinical research and highlights the statistical fragility of findings from smaller studies. The failure of SURVIVE to confirm a survival benefit is a primary reason for the drug's continued investigational status in the United States.

Furthermore, the collective results of these trials reveal a critical disconnect between surrogate endpoints and hard clinical outcomes. Levosimendan consistently demonstrates an ability to improve hemodynamics (LIDO), alleviate symptoms (REVIVE II), and lower biomarkers of cardiac stress (REVIVE II, SURVIVE). Yet, this array of short-term benefits does not translate into a proven reduction in long-term mortality (SURVIVE) and may even be accompanied by an increase in adverse events and a potential mortality signal (REVIVE II). This paradox suggests a crucial trade-off: the benefits of potent inodilation may be offset by the risks of hypotension and arrhythmia. This reframes the central clinical question from "Does Levosimendan work?" to a more nuanced inquiry: "For which specific patients does the benefit of symptomatic and hemodynamic improvement outweigh the risks and the lack of a proven survival advantage?" A retrospective subgroup analysis of the SURVIVE trial provided a potential answer, suggesting that patients with a prior history of heart failure or those on baseline beta-blocker therapy may derive greater benefit, hinting at a specific therapeutic niche.[1]

Table 2: Comparative Summary of Pivotal Levosimendan Trials (LIDO, REVIVE II, SURVIVE)

Feature	LIDO (2002)	REVIVE II (2005/2013)	SURVIVE (2007)
Design	Randomized, Double-Blind, Double-Dummy	Randomized, Double-Blind, Placebo-Controlled	Randomized, Double-Blind, Double-Dummy
Patient Population	N=203; Severe low-output HF requiring inotropes	N=600; ADHF with LVEF ≤35% and dyspnea at rest	N=1327; ADHF requiring inotropes, LVEF ≤30%
Comparator	Dobutamine	Placebo (plus standard therapy)	Dobutamine
Primary Endpoint	Hemodynamic improvement at 24h (↑CO & ↓PCWP)	Composite of clinical improvement vs. worsening over 5 days	All-cause mortality at 180 days
Primary Outcome	Superior to Dobutamine (28% vs. 15% achieved endpoint, p=0.022)	Superior to Placebo (More improvement, less worsening, p=0.015)	No significant difference (26% vs. 28% mortality, p=0.40)
Key Mortality Finding	Lower 180-day mortality vs. Dobutamine (26% vs. 38%, p=0.029)	Numerically higher 90-day mortality vs. Placebo (15.1% vs. 11.6%, NS)	No difference in 180-day mortality vs. Dobutamine
Key Adverse Events	Less myocardial ischemia and arrhythmia than dobutamine	More hypotension and atrial fibrillation than placebo	More atrial fibrillation and hypokalemia; less cardiac failure than dobutamine
Source(s)	21	34	31

Section 5: Comparative Analysis: Levosimendan in the Inotrope Armamentarium

The decision to use Levosimendan is made in the context of available alternatives, primarily the beta-agonist dobutamine and the PDE-III inhibitor milrinone. A direct comparison of their properties is essential for rational therapeutic selection.

5.1. Levosimendan versus Dobutamine

The most direct and heavily studied comparison is between Levosimendan and dobutamine. While the SURVIVE trial showed no difference in the hard endpoint of mortality, several key distinctions guide clinical choice.[32] The most critical of these is the interaction with beta-blockers. Beta-blocker therapy is a cornerstone of long-term management for chronic heart failure, meaning many patients who present with an acute decompensation are already taking these medications. Dobutamine, as a beta-agonist, has its mechanism of action directly antagonized by beta-blockers, leading to attenuated efficacy. Levosimendan's mechanism is independent of beta-adrenergic receptors, and thus its clinical effect is not diminished by concomitant beta-blocker use.[1] This provides a clear, evidence-based rationale for preferring Levosimendan in this large and common patient subgroup. In terms of safety, Levosimendan is more frequently associated with hypotension and atrial fibrillation, whereas dobutamine carries a greater risk of increasing myocardial oxygen demand and is associated with a higher rate of reported cardiac failure as an adverse event.[6]

5.2. Levosimendan versus Milrinone

Both Levosimendan and milrinone are classified as inodilators, but their mechanisms differ. Milrinone is a pure PDE-III inhibitor, while Levosimendan acts primarily as a calcium sensitizer with secondary PDE-III inhibitory and KATP​ channel-opening properties.[6] Head-to-head comparative data are less robust than for dobutamine but often come from the cardiac surgery setting. One trial in patients with post-cardiopulmonary bypass low cardiac output syndrome (LCOS) found Levosimendan to be equally effective as dobutamine and superior to milrinone in improving hemodynamic parameters.[8] Another study in a similar setting found that Levosimendan produced more significant improvements in cardiac output and vascular resistance compared to milrinone.[42] Mechanistically, Levosimendan is considered less arrhythmogenic at therapeutic doses because it does not cause the same degree of increase in intracellular cAMP and calcium as PDE-III inhibitors.[24]

Context from the DOREMI trial, a recent head-to-head comparison of dobutamine and milrinone in cardiogenic shock, is also relevant. The trial found no significant difference in a composite primary outcome of major adverse events, suggesting that for many patients, the choice between the two conventional inotropes may not significantly impact outcomes.[43] This finding underscores the persistent need for a superior agent, a role that Levosimendan was developed to fill.

Table 3: Comparative Profile of Inodilators: Levosimendan, Dobutamine, and Milrinone

Feature	Levosimendan	Dobutamine	Milrinone
Primary Mechanism	Calcium sensitization (Troponin C); KATP​ channel opening	β1 and β2 adrenergic agonism	Phosphodiesterase-III (PDE-III) inhibition
Hemodynamic Effects	↑ Inotropy, ↓ Preload, ↓ Afterload	↑ Inotropy, mild ↓ Afterload	↑ Inotropy, ↓ Preload, ↓ Afterload
Effect on MVO2	No significant increase	Significant increase	Mild to moderate increase
Arrhythmia Risk	Moderate (Atrial Fibrillation)	High (Tachyarrhythmias)	Moderate to High (Tachyarrhythmias)
Primary Safety Concern	Hypotension	Tachycardia, Myocardial Ischemia	Hypotension, Arrhythmia
Half-Life	~1 hr (parent); 75-80 hr (active metabolite)	2-3 minutes	~2.5 hours
Use with Beta-Blockers	Efficacy preserved	Efficacy attenuated	Efficacy preserved
Key Clinical Advantage	Effective with beta-blockade; no ↑ MVO2; sustained effect	Rapid onset/offset, easy titration	Effective with beta-blockade; pulmonary vasodilation
Key Disadvantage	Hypotension; long-acting effect not easily reversible	↑ MVO2; arrhythmogenic; efficacy reduced by beta-blockers	Hypotension; requires renal dose adjustment
Source(s)	1	6	6

Section 6: Regulatory Landscape and Prescribing Information

The clinical availability and use of Levosimendan are heavily influenced by a divergent global regulatory history, which itself is a direct consequence of the evolving clinical trial evidence.

6.1. Global Regulatory Status

Levosimendan was originally developed by the Orion Corporation, which first sought approval from the U.S. Food and Drug Administration (FDA) in 1998.[1] The FDA requested additional trials, leading Orion to withdraw the application in 1999.[1] The regulatory trajectory in Europe was different. Based on the promising data from early trials, including the LIDO study, the drug was first approved in Sweden in 2000. This was followed by mutual recognition procedures that led to its approval in many other European Union countries starting in 2001, including Finland, Spain, and Italy.[1] Today, Levosimendan is approved in approximately 60 countries across Europe, South America, and Asia.[1]

However, it remains unapproved for ADHF in North America (USA and Canada).[1] The failure of the large SURVIVE and REVIVE II trials to demonstrate a clear survival benefit, coupled with safety concerns, has prevented FDA approval. This regulatory divergence highlights how the timing of review relative to the maturation of clinical evidence, as well as differing regulatory philosophies regarding surrogate versus hard endpoints, can lead to starkly different outcomes for the same drug.

In a novel development, the European Medicines Agency (EMA) granted Levosimendan orphan drug designation in 2018 for the treatment of amyotrophic lateral sclerosis (ALS), based on preclinical data suggesting it may improve the function of respiratory muscles.[48] In the United States, the development focus has pivoted entirely. Tenax Therapeutics is now advancing Levosimendan through Phase 3 trials for a new indication, Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), using a novel oral formulation.[1]

6.2. Summary of Product Characteristics (Simdax®)

The following prescribing information is synthesized from the official Summary of Product Characteristics (SmPC) for Simdax® and other regulatory documents from jurisdictions where it is approved.

Indication: Levosimendan is indicated for the short-term treatment of acutely decompensated severe chronic heart failure (ADHF) in adult patients where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate.[1]

Dosage and Administration: Simdax is for in-hospital use only and must be administered in a setting with adequate monitoring facilities.[17] The 2.5 mg/mL concentrate must be diluted prior to administration, typically with 5% glucose solution, to a final concentration of 0.025 mg/mL or 0.05 mg/mL.[1] The infusion can be administered via a peripheral or central intravenous line.[17] The recommended infusion duration is 24 hours. The infusion rate should be individualized based on the patient's clinical condition and response, typically starting at 0.1 mcg/kg/min. This may be titrated down to 0.05 mcg/kg/min in case of hypotension or tachycardia, or up to a maximum of 0.2 mcg/kg/min if a greater hemodynamic effect is required.[25] While an initial loading dose is described in the SmPC, it is often omitted in clinical practice to reduce the risk of acute hypotension.[25]

Contraindications: Levosimendan is contraindicated in patients with:

• Known hypersensitivity to the drug or its excipients.[14]
• Severe hypotension and tachycardia.[1]
• Significant mechanical obstructions affecting ventricular filling or outflow (e.g., severe aortic stenosis, hypertrophic cardiomyopathy, constrictive pericarditis).[1]
• Severe renal impairment (creatinine clearance < 30 mL/min).[27]
• Severe hepatic impairment.[13]
• A history of the specific arrhythmia Torsades de Pointes.[1]

Adverse Drug Reactions: The most frequently reported adverse reactions reflect the drug's potent hemodynamic effects.

• Very Common (≥1/10 of patients): Headache, Hypotension, Ventricular Tachycardia.[27]
• Common (≥1/100 to <1/10): Hypokalemia, Insomnia, Dizziness, Atrial Fibrillation, Tachycardia, Myocardial Ischemia, Extrasystoles, Heart Failure, Nausea, Vomiting, Constipation, Diarrhea.[1]

Warnings and Precautions:

• Monitoring: Due to the long half-life of the active metabolite, continuous ECG, blood pressure, and heart rate monitoring is required during the infusion and should continue for at least 3 days (or until the patient is clinically stable) after the infusion is stopped.[27]
• Electrolytes: Serum potassium levels must be corrected prior to administration and monitored throughout treatment, as the infusion can cause hypokalemia.[27]
• Volume Status: The drug should be used with caution in patients with low systolic blood pressure or those at risk of hypotension. Correcting hypovolemia before starting the infusion is critical to mitigate this risk.[13]

Section 7: Evolving Roles and Future Horizons

Despite its complex history in ADHF, Levosimendan's unique pharmacology continues to drive investigation into new therapeutic roles, both in off-label critical care settings and in formal clinical development for new indications.

7.1. Off-Label and Investigational Use in Critical Care

Cardiogenic Shock (CS): Levosimendan is increasingly used as a therapeutic option in CS. Its ability to provide inotropic support without increasing myocardial oxygen consumption makes it a theoretically attractive agent in this setting, where myocardial ischemia is often a driving factor.[5] Small studies and clinical experience suggest it can improve hemodynamic parameters and may favorably modulate oxidative stress in CS patients.[50] It is often considered a valuable addition to the therapeutic armamentarium for CS, particularly as a bridge to recovery or other therapies.[49]

Sepsis-Induced Myocardial Dysfunction (SIMD): The role of Levosimendan in septic shock is one of the most controversial topics in critical care medicine. On one hand, its catecholamine-independent mechanism, vasodilatory properties that could improve microcirculatory flow, and potential organ-protective effects make it an ideal theoretical candidate for treating the myocardial depression seen in sepsis.[23] On the other hand, the landmark

LeoPARDS trial (2016), which randomized septic shock patients requiring vasopressors to Levosimendan or placebo, found no improvement in organ dysfunction and was associated with an increased risk of supraventricular arrhythmias and a lower likelihood of successful weaning from mechanical ventilation.[23] Critics of the trial note that it did not specifically select for patients with confirmed cardiac dysfunction. More recent meta-analyses that have focused specifically on patients with documented SIMD (e.g., low left ventricular ejection fraction [LVEF]) have suggested that Levosimendan may improve cardiac index and lactate clearance, though a mortality benefit remains unproven.[52] Given this conflicting evidence, the official Surviving Sepsis Campaign guidelines currently recommend against the routine use of Levosimendan in septic shock.[23]

Perioperative Cardiac Surgery: Levosimendan is frequently used in the perioperative setting to prevent or treat low cardiac output syndrome (LCOS) following cardiac surgery, especially in patients with poor preoperative ventricular function. Evidence suggests it can improve postoperative hemodynamics and may reduce the need for mechanical circulatory support, such as an intra-aortic balloon pump (IABP).[24]

7.2. The Future: A "Second Act" for a Controversial Drug

The most significant future development for Levosimendan is its potential "second act" in North America, driven by Tenax Therapeutics.[16] This involves a strategic pivot away from the challenging ADHF with reduced ejection fraction (HFrEF) market towards a distinct condition with a major unmet medical need:

Pulmonary Hypertension associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF).[1] There are currently no approved therapies for this debilitating condition. Levosimendan's known ability to improve cardiac function and induce vasodilation (including in the pulmonary circulation) makes it a strong candidate.[42] This development program is centered on a novel

oral formulation (TNX-103), signaling a shift from acute, in-hospital use to chronic, outpatient management.[16]

The cornerstone of this program is the ongoing LEVEL trial (NCT05983250), a large, international, placebo-controlled Phase 3 study. It aims to evaluate the efficacy of oral Levosimendan in improving exercise capacity, measured by the change in 6-Minute Walk Distance (6MWD) over 12 weeks, in patients with PH-HFpEF.[54] Success in this trial could lead to the first FDA approval for Levosimendan and revitalize a drug with a complex past by establishing it in an entirely new therapeutic area.

Other ongoing research includes a Phase 4 trial investigating Levosimendan's effect on cardiac function following Transcatheter Aortic Valve Replacement (TAVR) in patients with severe aortic stenosis and pre-existing cardiac insufficiency (NCT06196177), further exploring its utility in structural heart disease interventions.[58]

Table 4: Selected Ongoing Phase 3/4 Clinical Trials of Levosimendan

Trial Identifier / Name	Phase	Condition / Indication	Intervention	Primary Endpoint	Est. Enrollment	Est. Completion
NCT05983250 / LEVEL	Phase 3	Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	Oral Levosimendan (TNX-103) vs. Placebo	Change in 6-Minute Walk Distance at Week 12	230	May 2028
NCT06196177	Phase 4	Cardiac Insufficiency after Transcatheter Aortic Valve Replacement (TAVR)	IV Levosimendan vs. Standard Care	Change in NT-proBNP levels	112	February 2025
NCT00527059	Phase 4	Acute Decompensated Heart Failure with Impaired Renal Function	IV Levosimendan vs. Placebo	Change in renal blood flow and GFR	N/A	Unknown
Source(s)	56

Section 8: Expert Synthesis and Clinical Recommendations

8.1. Synthesis of Evidence: The Levosimendan Paradox

Levosimendan presents a compelling paradox for clinicians. It is a pharmacologically elegant drug with a unique, energy-efficient mechanism of action that provides demonstrable short-term symptomatic and hemodynamic benefits in patients with acute heart failure. However, this physiological improvement has not translated into a proven survival advantage in large-scale, definitive clinical trials. Furthermore, its potent vasodilatory effects are associated with significant adverse events, primarily hypotension and arrhythmias, which may offset its benefits and contribute to the neutral mortality findings. The central challenge in its clinical use, therefore, is to harness its benefits while mitigating its risks through careful patient selection and management.

8.2. Identifying the Optimal Patient Profile

The accumulated evidence suggests that Levosimendan is not a first-line agent for all patients with ADHF but rather a valuable tool for a specific, well-defined clinical niche. The patient most likely to derive a net benefit from Levosimendan therapy typically exhibits the following characteristics:

• A "Cold and Wet" Profile: The patient presents with clear signs of low cardiac output syndrome (e.g., cool extremities, oliguria, narrow pulse pressure) and volume overload (e.g., pulmonary congestion, peripheral edema).
• Concomitant Beta-Blocker Therapy: The patient is on chronic, guideline-directed beta-blocker therapy. In this scenario, the efficacy of dobutamine is attenuated, making Levosimendan a more logical choice.[1]
• Adequate Blood Pressure: The patient is euvolemic or hypervolemic and has a systolic blood pressure sufficient to tolerate the predictable vasodilatory effects of the drug (e.g., SBP > 90-100 mmHg). Patients who are hypovolemic or severely hypotensive at baseline are poor candidates.[13]
• Myocardial Ischemia: The patient has underlying ischemic heart disease, where Levosimendan's ability to improve contractility without increasing myocardial oxygen demand and its potential cardioprotective effects offer a theoretical advantage over catecholamines.[6]
• Post-Cardiotomy Setting: The patient is in the postoperative period following cardiac surgery and is experiencing LCOS or difficulty weaning from cardiopulmonary bypass.[53]

8.3. Actionable Clinical Recommendations

To maximize the benefit-risk ratio of Levosimendan, the following clinical practices are recommended:

1. Prioritize Patient Selection: Adhere strictly to the optimal patient profile described above. Avoid use in patients with severe baseline hypotension, uncorrected hypovolemia, or significant mechanical cardiac obstructions.
2. Omit the Loading Dose: In the majority of critically ill patients, it is prudent to initiate therapy without a loading bolus. This mitigates the risk of precipitous and potentially dangerous hypotension. A gradual onset of action achieved by starting directly with the maintenance infusion is a safer approach.
3. Adopt a "Start Low, Go Slow" Dosing Strategy: Begin the infusion at a conservative rate (e.g., 0.05 to 0.1 mcg/kg/min) and titrate according to the patient's hemodynamic response and tolerance.
4. Perform a Pre-Infusion Checklist: Before initiating the infusion, ensure that significant hypokalemia and hypovolemia have been corrected. This is a critical step to minimize the risk of arrhythmias and severe hypotension, respectively.
5. Institute Extended Monitoring: Given the long half-life of the active OR-1896 metabolite, monitoring must extend well beyond the 24-hour infusion period. Continuous ECG, blood pressure, and heart rate monitoring should be maintained for at least 3 to 5 days post-infusion to promptly detect and manage delayed hypotension or arrhythmias.

In conclusion, Levosimendan remains a niche but valuable inodilator for a carefully selected group of patients with acute decompensated heart failure. Its current role is defined by its unique advantages in the setting of beta-blockade and myocardial ischemia. While its story in ADHF is one of unfulfilled promise in terms of mortality reduction, its future may be redefined by the ongoing Phase 3 trials investigating its potential as a first-in-class oral therapy for the challenging condition of PH-HFpEF.

Works cited

1. en.wikipedia.org, accessed July 31, 2025, https://en.wikipedia.org/wiki/Levosimendan
2. Levosimendan | C14H12N6O | CID 3033825 - PubChem, accessed July 31, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Levosimendan
3. Levosimendan: current data, clinical use and future development - PMC, accessed July 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3868185/
4. Breaking Boundaries: Novel Effects of Levosimendan in Various Diseases-Scilight, accessed July 31, 2025, https://www.sciltp.com/journals/ijddp/article/view/345
5. Evidence-based use of levosimendan in different clinical settings - Oxford Academic, accessed July 31, 2025, https://academic.oup.com/eurheartj/article/27/16/1908/2888090
6. An update on levosimendan in acute cardiac care: applications and ..., accessed July 31, 2025, https://www.tandfonline.com/doi/full/10.1080/14779072.2021.1905520
7. Levosimendan: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed July 31, 2025, https://go.drugbank.com/drugs/DB00922
8. Comparison of Levosimendan, Milrinone and Dobutamine in ..., accessed July 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5296550/
9. Abbott reports levosimendan (Simdax®) results from large mortality trial in patients with acute decompensated heart failure - Orion Pharma, accessed July 31, 2025, https://www.orionpharma.com/newsroom/all-news/releases/stock-releases/2005/abbott-reports-levosimendan-simdax-results-from-large-mortality-trial-in-patients-with-acute-decompensated-heart--failure/
10. Levosimendan (OR 1259, (R)-Simendan, CAS Number: 141505-33-1) | Cayman Chemical, accessed July 31, 2025, https://www.caymanchem.com/product/16128/levosimendan
11. Levosimendan - Deranged Physiology, accessed July 31, 2025, https://derangedphysiology.com/main/cicm-primary-exam/cardiovascular-system/Chapter-978/levosimendan
12. Levosimendan | CAS 141505-33-1 | SCBT - Santa Cruz Biotechnology, accessed July 31, 2025, https://www.scbt.com/p/levosimendan-141505-33-1
13. Simdax - Medsafe, accessed July 31, 2025, https://www.medsafe.govt.nz/consumers/cmi/s/simdax.pdf
14. Simdax 2.5 mg/ml concentrate for solution for infusion, accessed July 31, 2025, https://docetp.mpa.se/LMF/Simdax%20concentrate%20for%20solution%20for%20infusion%20ENG%20PL_09001bee807a76cc.pdf
15. NEW ZEALAND DATA SHEET - Medsafe, accessed July 31, 2025, https://medsafe.govt.nz/profs/Datasheet/s/Simdaxinj.pdf
16. What is levosimendan used for? - Drugs.com, accessed July 31, 2025, https://www.drugs.com/medical-answers/levosimendan-3571790/
17. 1 Notice : information de l'utilisateur Simdax 2,5 mg/ml solution à diluer pour perfusion lévosimendan Veuillez lire attenti - AFMPS, accessed July 31, 2025, https://app.fagg-afmps.be/pharma-status/api/files/62bc5adf1e5c015ab3c42aa1
18. Levosimendan | C14H12N6O - ChemSpider, accessed July 31, 2025, https://www.chemspider.com/Chemical-Structure.2298414.html
19. 141505-33-1|(R)-N-(4-(4-Methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)carbonohydrazonoyl dicyanide - BLDpharm, accessed July 31, 2025, https://www.bldpharm.com/products/141505-33-1.html
20. Levosimendan = 98 HPLC 141505-33-1 - Sigma-Aldrich, accessed July 31, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/l5545
21. Efficacy and safety of intravenous levosimendan compared with ..., accessed July 31, 2025, https://pubmed.ncbi.nlm.nih.gov/12133653/
22. Scientific Evaluation Report of the Medicines Evaluation Board of the Netherlands on the assessment of applications for Levos - CBG-Meb, accessed July 31, 2025, https://www.cbg-meb.nl/binaries/college-ter-beoordeling-van-geneesmiddelen/documenten/rapporten/2016/02/04/ser-levosimendan/160204-scientificevaluationreport-levosimendan.pdf
23. Levosimendan for sepsis-induced myocardial dysfunction: friend or ..., accessed July 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11752121/
24. Comparison of Levosimendan with Milrinone and Dobutamine - ResearchGate, accessed July 31, 2025, https://www.researchgate.net/figure/Comparison-of-Levosimendan-with-Milrinone-and-Dobutamine_tbl1_7215576
25. Levosimendan ICU SOP 020 - Cardiff Critical Care, accessed July 31, 2025, https://cardiffcriticalcare.co.uk/wp-content/uploads/2020/11/Levosimendan-ICU-SOP-020.pdf
26. SIMDAX® STARTER'S GUIDANCE, accessed July 31, 2025, https://www.simdax.com/siteassets/downloadable-materials/simdax-starter-guide-2017_low.pdf
27. Lévosimendan : substance active à effet thérapeutique - VIDAL, accessed July 31, 2025, https://www.vidal.fr/medicaments/substances/levosimendan-21840.html
28. Levosimendan Infusion versus Dobutamine - LIDO - American College of Cardiology, accessed July 31, 2025, https://www.acc.org/latest-in-cardiology/clinical-trials/2010/02/23/19/10/lido
29. SIMDAX conc perf 12.5 mg/5ml C01CX08 Lévosimendan - compendium.ch, accessed July 31, 2025, https://compendium.ch/fr/product/1254134-simdax-conc-perf-12-5-mg-5ml
30. Summary Product Characteristics - SIMDAX, accessed July 31, 2025, https://www.simdax.com/siteassets/simdax-spc.pdf
31. Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure: The SURVIVE Randomized Trial | Request PDF - ResearchGate, accessed July 31, 2025, https://www.researchgate.net/publication/6357329_Levosimendan_vs_Dobutamine_for_Patients_With_Acute_Decompensated_Heart_Failure_The_SURVIVE_Randomized_Trial
32. Levosimendan vs dobutamine for patients with acute ... - PubMed, accessed July 31, 2025, https://pubmed.ncbi.nlm.nih.gov/17473298/
33. Efficacy and safety of intravenous Levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial - ResearchGate, accessed July 31, 2025, https://www.researchgate.net/publication/11247527_Efficacy_and_safety_of_intravenous_Levosimendan_compared_with_dobutamine_in_severe_low-output_heart_failure_the_LIDO_study_A_randomised_double-blind_trial
34. Abbott Laboratories Reports Improved Clinical Course With Levosimendan When Added To Standard Therapy In Acute Decompensated Heart Failure Trial - BioSpace, accessed July 31, 2025, https://www.biospace.com/abbott-laboratories-reports-improved-clinical-course-with-levosimendan-when-added-to-standard-therapy-in-acute-decompensated-heart-failure-trial
35. REVIVE II - American College of Cardiology, accessed July 31, 2025, https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2010/02/23/19/18/REVIVE-II
36. REVIVE-2: Levosimendan improves five-day clinical status in acute HF - Medscape, accessed July 31, 2025, https://www.medscape.com/viewarticle/788005
37. REVIVE II and SURVIVE: Use of Levosimendan for the Treatment of ..., accessed July 31, 2025, https://www.medscape.org/viewarticle/523043
38. Levosimendan Studies Finally Published - Medscape, accessed July 31, 2025, https://www.medscape.com/viewarticle/782117
39. Levosimendan vs Dobutamine for Patients With ADHF: SURVIVE Randomized Trial, accessed July 31, 2025, https://www.medscape.com/viewarticle/557794
40. Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support, accessed July 31, 2025, https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2010/02/23/19/21/SURVIVE
41. a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure. | ClinicalTrials.gov, accessed July 31, 2025, https://clinicaltrials.gov/study/NCT00348504?rank=1
42. Levosimendan Versus Milrinone in the Management of Impaired Left Ventricular Function in Patients Undergoing Coronary Artery Bypass Graft Surgery - The Open Anesthesia Journal, accessed July 31, 2025, https://openanesthesiajournal.com/VOLUME/13/PAGE/59/FULLTEXT/
43. Milrinone as Compared with Dobutamiune in the treatment of Cardiogenic Shock Reviewer: Rebecca Wahrmund, PharmD Background, accessed July 31, 2025, https://apa.memberclicks.net/assets/AAHP/Website/Wahrmund%20AAHP%20Journal%20Club%20handout%20Milrinone%20vs.%20Dobutamine.pdf
44. Critical Care Alert: Milrinone vs. Dobutamine in the Treatment of Cardiogenic Shock - EMRA, accessed July 31, 2025, https://www.emra.org/emresident/article/critcare-alert-cardiogenic-shock
45. Orion Pharma's heart failure drug Simdax to be approved in eight european countries, accessed July 31, 2025, https://www.orionpharma.com/newsroom/all-news/releases/stock-releases/2001/orion-pharmas-heart-failure-drug-simdax-to-be-approved-in-eight-european-countries/
46. Active substance: levosimendan List of nationally authorised ... - EMA, accessed July 31, 2025, https://www.ema.europa.eu/en/documents/psusa/levosimendan-list-nationally-authorised-medicinal-products-psusa00001858201609_en.pdf
47. PSUSA NAP EPAR (variation) template - example LL - empty document - EMA, accessed July 31, 2025, https://www.ema.europa.eu/en/documents/psusa/levosimendan-list-nationally-authorised-medicinal-products-psusa00001858201909_en.pdf
48. PSO 174-17 Levosimendan - EMA - European Union, accessed July 31, 2025, https://www.ema.europa.eu/en/documents/orphan-designation/eu3181980-public-summary-opinion-orphan-designation-levosimendan-treatment-amyotrophic-lateral-sclerosis_en.pdf
49. Levosimendan in Cardiogenic Shock | ECR Journal - European Cardiology Review, accessed July 31, 2025, https://www.ecrjournal.com/articles/levosimendan-promising-pharmacotherapy-cardiogenic-shock-comprehensive-review?language_content_entity=en
50. Levosimendan Improves Oxidative Balance in Cardiogenic Shock/Low Cardiac Output Patients - MDPI, accessed July 31, 2025, https://www.mdpi.com/2077-0383/9/2/373
51. Levosimendan Improves Oxidative Balance in Cardiogenic Shock ..., accessed July 31, 2025, https://www.mdpi.com/2077-0383/9/2/373/htm
52. Efficacy and safety of levosimendan in patients with sepsis: a systematic review and network meta-analysis - Frontiers, accessed July 31, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1358735/full
53. Levosimendan in patients with low-output heart failure: Lessons from the LIDO trial, accessed July 31, 2025, https://www.researchgate.net/publication/8993812_Levosimendan_in_patients_with_low-output_heart_failure_Lessons_from_the_LIDO_trial
54. CLINICAL TRIAL / NCT05983250 - UChicago Medicine, accessed July 31, 2025, https://www.uchicagomedicine.org/find-a-clinical-trial/clinical-trial/irb231834
55. LEVosimendan to Improve Exercise Limitation in Patients with PH-HFpEF - UCSF Clinical Trials, accessed July 31, 2025, https://clinicaltrials.ucsf.edu/trial/NCT05983250
56. LEVosimendan to Improve Exercise Limitation in Patients with PH-HFpEF | ClinicalTrials.gov, accessed July 31, 2025, https://clinicaltrials.gov/study/NCT05983250
57. LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF (LEVEL), accessed July 31, 2025, https://www.templehealth.org/services/heart-vascular/research-clinical-trials/levosimendan-to-improve-exercise-limitation-in-patients-with-ph-hfpef
58. Effects of Levosimendan on Cardiac Function After TAVR in Patients With Heart Failure, accessed July 31, 2025, https://clinicaltrials.gov/study/NCT06196177
59. Levosimendan Unknown Status Phase 4 Trials for Impaired Renal Function / Cardiac Failure Treatment | DrugBank Online, accessed July 31, 2025, https://go.drugbank.com/drugs/DB00922/clinical_trials?conditions=DBCOND0040020%2CDBCOND0038927&phase=4&purpose=treatment&status=unknown_status